You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. AEROVATE THERAPEUTICS INC

Aerovate Therapeutics Inc XNAS: AVTE

Aerovate Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

2.76 -0.01 (-0.36%)

89.08% Fall from 52W High

984.9K XNAS Volume

High volume today

XNAS 22 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Split
Aerovate Therapeutics Inc has split the face value of its shares from $1 to $35 on 29 Apr 2025. See details

Aerovate Therapeutics Inc Key Metrics

Select

Market Capitalization

Below industry Median
80

PE TTM

Negative PE TTM
-1.1

PEG TTM

Negative PEG TTM
-0.1

Price to Book

Below industry Median
1

Institutional holding current Qtr %

High in industry
99.7

Net Profit Qtr Growth YoY %

High in industry
73.4

Net Profit TTM Growth %

Below industry Median
7.8

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

8.8

ROE Annual %

Negative ROE Annual %
-74.9

RoA Annual %

Negative RoA Annual %
-67
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
10.7 / 100
Momentum Score
Technically Moderately Bullish
63.9 / 100
Analyst Price Target
No estimates available

20

S

10

W

3

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Aerovate Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Aerovate Therapeutics Inc Stock Analysis

Aerovate Therapeutics Inc stock analysis with key metrics, changes, and trends.

Aerovate Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$69.63 M7.8%positive

Annual Net Profit rose 7.8% in the last year to $69.63 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-1.15-negative

Price to Earning Ratio is -1.15, which is negative.

Stock Price$2.76-87.48%negative

Stock Price fell 87.48% and underperformed its sector by 96.63% in the past year.

Quarterly Net profit$5.43 M73.4%positive

Quarterly Net profit rose 73.4% YoY to $5.43 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio0.01-positive

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-74.91 %-74.91%negative

Return on Equity(ROE) for the last financial year was -74.91%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding11.00 %0.02%positive

Mutual Fund Holding increased by 0.02% in the last quarter to 11.

Institutional Holding99.74 %0.03%positive

Institutional Holding increased by 0.03% in the last quarter to 99.74.

VIEW LESS


Loading data..

Aerovate Therapeutics Inc - Company Profile

What does Aerovate Therapeutics Inc do?

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Aerovate Therapeutics Inc Management structure

All Gross Remunerations are in USD
Mr. George A. Eldridge
Chief Financial Officer, Treasurer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Timothy P. Noyes
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year

Aerovate Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Maha Katabi, PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. Donald J. Santel
Independent Director
-
2024
Gross Remuneration
Year
Mr. Mark T. Iwicki
Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. Timothy P. Noyes
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year
Ms. Allison Dorval
Independent Director
-
2024
Gross Remuneration
Year
Dr. Joshua Resnick, M.B.A.,M.D.
Independent Director
-
2024
Gross Remuneration
Year

Aerovate Therapeutics Inc FAQ

How is Aerovate Therapeutics Inc today?
Aerovate Therapeutics Inc today is trading in the red, and is down by -0.36% at 2.76.
Aerovate Therapeutics Inc is currently trading down -0.36% on an intraday basis. In the past week the stock rose 1.85%. stock has been up 8.24% in the past quarter and fell -87.48% in the past year. You can view this in the overview section.